Figure 2. Genetic or antibody-mediated depletion of Ly6G^Pos cells decreases Mtb burden without affecting other immune cells.

a CFUs per lung at 25 days PI within Bl6 WT, C3HebFeJ, or Nos2^−/− mice treated with anti-Ly6g depleting antibody (1A8) or isotype control (2A3). b Representative scatterplots of lung cells from infected Bl6 WT (top mid) or Genista (top right) mice treated with aminoguanidine (AG), with quantified CFUs (bottom left), Ly6G^Mid cells (bottom mid), or Ly6G^High cells (bottom right) per lung at 56 days PI with or without AG treatment. c Quantification of the indicated immune cells in the lungs of AG-treated Bl6 WT mice or AG-treated Genista mice at 56 days PI. N = 3–7 mice per group and error bars represent standard deviation between biological replicates within each group. Statistical values based on unpaired Student’s T-test or one-way ANOVA with Tukey’s Multiple Comparison analysis.